Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas

Vincent A van Vugt; David E Piccioni; Bradley D Brown; Tiffany Brown; Marlon G Saria; Tiffany Juarez; Santosh Kesari; Marlon Garzo Saria

doi:10.2217/cns.14.29

Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas

Vincent A van Vugt
, David E Piccioni
, Bradley D Brown
, Tiffany Brown
, Marlon G Saria
, Tiffany Juarez
, Santosh Kesari
, Marlon Garzo Saria

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.

PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).

RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.

CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.

Original language	English
Pages (from-to)	257-265
Number of pages	9
Journal	CNS oncology
Volume	3
Issue number	4
DOIs	https://doi.org/10.2217/cns.14.29
State	Published - Jul 1 2014

Keywords

alternative regimens
chemotherapy
glioblastoma
glioma temodar
safety
temozolomide

Access to Document

10.2217/cns.14.29

Cite this

@article{7e9565596a6740c7abc3232123205b3c,

title = "Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas",

abstract = "AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.PATIENTS \& METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13\%) experienced grade 3 nausea/vomiting and six patients (40\%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53\%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25\%. Twelve patients exhibited stable disease (86\%), one patient (7\%) had progressive disease and one patient (7\%) showed a partial response.CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.",

keywords = "alternative regimens, chemotherapy, glioblastoma, glioma temodar, safety, temozolomide",

author = "\{van Vugt\}, \{Vincent A\} and Piccioni, \{David E\} and Brown, \{Bradley D\} and Tiffany Brown and Saria, \{Marlon G\} and Tiffany Juarez and Santosh Kesari and Saria, \{Marlon Garzo\}",

note = "We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.Fifteen adult patients were treated; 14 were treated with 300 mg/m[2] and one treated with 250 mg/m[2] .We reviewed ...",

year = "2014",

month = jul,

day = "1",

doi = "10.2217/cns.14.29",

language = "English",

volume = "3",

pages = "257--265",

journal = "CNS oncology",

issn = "2045-0907",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas

AU - van Vugt, Vincent A

AU - Piccioni, David E

AU - Brown, Bradley D

AU - Brown, Tiffany

AU - Saria, Marlon G

AU - Juarez, Tiffany

AU - Kesari, Santosh

AU - Saria, Marlon Garzo

N1 - We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.Fifteen adult patients were treated; 14 were treated with 300 mg/m[2] and one treated with 250 mg/m[2] .We reviewed ...

PY - 2014/7/1

Y1 - 2014/7/1

N2 - AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.

AB - AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.

KW - alternative regimens

KW - chemotherapy

KW - glioblastoma

KW - glioma temodar

KW - safety

KW - temozolomide

UR - https://www.scopus.com/pages/publications/84964313797

U2 - 10.2217/cns.14.29

DO - 10.2217/cns.14.29

M3 - Article

C2 - 25286037

SN - 2045-0907

VL - 3

SP - 257

EP - 265

JO - CNS oncology

JF - CNS oncology

IS - 4

ER -

Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this